BIOMATRIX SPRX SELECTED AS AUTHORIZED PROVIDER OF HEMLIBRA
First New Product for Hemophilia Inhibitor Patients in Nearly 20 Years
Media Contact: Tara Marchese
Corporate Director of Marketing
Weston, FL – December 14, 2017 – BioMatrix SpRx today announced they have been selected as an authorized specialty pharmacy provider of Genentech’s new drug, Hemlibra (emicizumab-kxwh). The product is indicated for pediatric and adult patients who have hemophilia A with inhibitors.
Receiving Breakthrough Therapy Designation by the FDA in 2015, Hemlibra is the first self-administered, subcutaneous therapy for hemophilia. Data from ongoing clinical studies indicates once weekly injections substantially reduce bleed rates. To review information regarding Hemlibra, including the full list of authorized providers, visit the Genentech Hemlibra webpage. www.hemlibra.com
Chief Clinical Officer David McCormick shares, “We are thrilled to partner with Genentech to offer Hemlibra. We have a long history of supporting patients with inhibitors and understand the unique challenges this community faces. We have witnessed the quality of life improvements this drug can provide, and are so proud to play our role in helping patients experience better health.”
About BioMatrix SpRx
BioMatrix SpRx, a portfolio company of Acon Investments and Triton Pacific Capital Partners, LLC., offers comprehensive nationwide specialty pharmacy services and digital health technology solutions for a range of chronic health conditions. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes Matrix Health Group, Factor Support Network, Medex BioCare, BiologicTx, and Elwyn Pharmacy Group.